WFDC2 and ovarian cancer: We have shown that HE4 has a better diagnostic performance than CA125 in younger women, and the combination of HE4 and CA125 detected all ovarian cancers (100% sensitivity) in women under 50 years, leading to the detection of 1 extra case for every additional 34 women referred to secondary care.